When Particle Therapy May Be Considered: By Clinical Situation
Particle therapy is not considered for every cancer patient.
In many cases, surgery, systemic therapy, conventional radiation therapy, or other local treatments may be more appropriate.
However, particle therapy may be reviewed in selected clinical situations where dose delivery, nearby critical organs, prior treatment history, or local treatment limitations are important considerations.
Clinical situations that may lead to particle therapy review include:
- Tumors located close to critical organs
- Re-irradiation after prior radiation therapy
- Local recurrence after previous treatment
- Unresectable or medically inoperable tumors
- Selected locally advanced cancers
- Pediatric or young adult cases where long-term tissue protection is important
- Cases where conventional radiation may be difficult due to surrounding normal tissue risk
The purpose of particle therapy is often related to dose concentration and normal tissue protection.
This may be relevant when the tumor is located near organs at risk, such as the brain, spinal cord, optic structures, salivary glands, lungs, liver, bowel, bladder, rectum, or other sensitive structures.
In re-irradiation cases, prior radiation dose records are especially important. Hospitals usually need to understand the previous radiation field, total dose, fractionation schedule, and the time interval since prior radiation.
For unresectable, recurrent, or locally advanced disease, particle therapy may be reviewed as part of a broader multidisciplinary decision. This does not mean that particle therapy is always appropriate or available.
Key factors for review may include:
- Cancer type and disease stage
- Current extent of disease
- Prior surgery, chemotherapy, immunotherapy, or radiation therapy
- Recent imaging findings
- Tumor location and nearby organs at risk
- General medical condition and performance status
- Whether treatment can be delivered safely within an appropriate timeline
For international patients, the practical question is whether a Korean particle therapy center can review the case and whether consultation or treatment may be clinically appropriate.
APIS helps coordinate preliminary communication and document submission to Korean hospitals for selected international cases.
* Final treatment decisions are determined solely by the treating hospitals and physicians.
